Clindamycin Label Updated to Include Dosing Information for Premature and Term Infants

Mother and baby

A Pediatric Trials Network (PTN) pharmacokinetic (PK) study recently contributed to a medication label change for the drug clindamycin.

This research effort, which involved analysis data from 4 studies (Pharmacokinetics of Antistaphylococcal Antibiotics in Infants, Pharmacokinetics of Understudied Drugs Administered to Children, and Safety and Pharmacokinetics of Multiple-Dose Intravenous and Oral Clindamycin, and Antibiotic Safety in Infants With Complicated Intra-abdominal Infections), determined the pharmacokinetics in premature and term infants for treatment of staphylococcal infections.

PTN researchers measured the levels of clindamycin in each infant participant, thereby helping to determine the best dose of these drugs to treat infections in these patients. The studies found that clindamycin behaves differently in premature infants than it does in older children and adults due to the immaturity of their metabolic and kidney pathways; thus, identifying the correct dosages of drugs like clindamycin represents a critical public health need.

Thanks to this collaborative effort among PTN researchers, authorized medical providers now have appropriate guidance on how to prescribe and administer clindamycin to infants.

To learn more about the PTN studies that informed the clindamycin label change, please visit the study pages below:

News icon

news